Martingale Asset Management’s Theravance Biopharma TBPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $759K | Buy |
68,841
+7,511
| +12% | +$82.8K | 0.02% | 526 |
|
|
2025
Q1 | $548K | Buy |
61,330
+2,680
| +5% | +$23.9K | 0.01% | 583 |
|
|
2024
Q4 | $552K | Buy |
58,650
+4,200
| +8% | +$39.5K | 0.01% | 586 |
|
|
2024
Q3 | $439K | Buy |
54,450
+6,870
| +14% | +$55.4K | 0.01% | 654 |
|
|
2024
Q2 | $403K | Buy |
47,580
+16
| +0% | +$136 | 0.01% | 645 |
|
|
2024
Q1 | $427K | Sell |
47,564
-1,100
| -2% | -$9.87K | 0.01% | 643 |
|
|
2023
Q4 | $547K | Sell |
48,664
-30,020
| -38% | -$337K | 0.01% | 592 |
|
|
2023
Q3 | $679K | Hold |
78,684
| – | – | 0.01% | 542 |
|
|
2023
Q2 | $814K | Buy |
78,684
+1,901
| +2% | +$19.7K | 0.02% | 500 |
|
|
2023
Q1 | $833K | Buy |
76,783
+16,041
| +26% | +$174K | 0.02% | 490 |
|
|
2022
Q4 | $682K | Buy |
+60,742
| New | +$682K | 0.01% | 565 |
|
|
2020
Q4 | – | Sell |
-11,200
| Closed | -$166K | – | 1038 |
|
|
2020
Q3 | $166K | Buy |
11,200
+1,400
| +14% | +$20.8K | ﹤0.01% | 987 |
|
|
2020
Q2 | $206K | Buy |
+9,800
| New | +$206K | ﹤0.01% | 989 |
|